Date: May 29 – 31, 2020
Location: Virtual
Location: Virtual
In collaboration with Northwestern University and Peking University Cancer Hospital, we are presenting a poster at the American Society of Clinical Oncology Virtual Scientific Program.
This study demonstrates that PredicineCARE blood-based ctDNA effectively detected the key mutations in HR+ metastatic breast cancer patients in US and China. Genomic landscape of patients with HR+ MBC at time of first recurrence or de-novo metastatic diagnosis in the US and China were compared and analyzed using PredicineCARE blood-based testing and notable differences in somatic variants was observed in the two cohorts.
Make sure to check out our poster presentation and our virtual exhibition to schedule a meeting with us!
Abstract # 1059 | Track: Breast Cancer – Metastatic
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China